The US Food and Drug Administration issued an Emergency Use Authorization for Pfizer-BioNTech Covid-19 vaccine on December 11, 2020, administered as two doses separated by 21 days, experiences Xinhua information company.
As of December 23, 2020, a complete of 1,893,360 first doses of Pfizer-BioNTech Covid-19 vaccine had been administered in the US, in response to the CDC report.
Reports of 4,393 adverse events had been submitted to the Vaccine Adverse Event Reporting System in the nation.
Among these, 175 case experiences have been recognized for additional assessment as attainable circumstances of extreme allergic response, together with anaphylaxis.
Twenty-one circumstances have been decided to be anaphylaxis, together with 17 in individuals with a documented historical past of allergic reactions or allergic reactions, seven of whom had a historical past of anaphylaxis, in response to the CDC.
Anaphylaxis is a life-threatening allergic response that does happen hardly ever after vaccination, with onset usually inside minutes to hours, mentioned the CDC.
Locations administering Covid-19 vaccines ought to adhere to CDC steerage to be used of the jabs, together with screening recipients for contraindications and precautions, having the required provides out there to handle anaphylaxis, implementing the beneficial post-vaccination commentary durations, and instantly treating suspected circumstances of anaphylaxis with an intramuscular injection of epinephrine, mentioned the CDC.